Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofutriben PK in Moderate Renal Impairment
NCT07227922Phase 1Recruiting
- Sponsor
- Sparrow Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of clofutriben in Cushing's syndrome (2 arms), sponsored by Sparrow Pharmaceuticals. Primary endpoints: Maximum plasma concentration at 6 days, Area under the plasma time-concentration curve from time zero to time t at 6 days and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
clofutriben
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT07227922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227922.